You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 783 Trial in progress: a phase 1/2 open-label study (IOV-GM1–201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
783 Trial in progress: a phase 1/2 open-label study (IOV-GM1–201) of TALEN-mediated PD-1–inactivated autologous tumor-infiltrating lymphocytes (TIL; IOV-4001) in patients with advanced melanoma and NSCLC
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to August 2024

AbstractFullPdf
Nov 2022294021
Dec 20227406
Jan 20234004
Feb 20235607
Mar 20233803
Apr 20236805
May 20232901
Jun 20234202
Jul 20233805
Aug 20232705
Sep 20233606
Oct 20234808
Nov 20234601
Dec 20236404
Jan 20243607
Feb 20242404
Mar 20244606
Apr 20244406
May 20243202
Jun 202456011
Jul 20245208
Aug 20246006
Total12500128